Neogenomics Inc.
NEO
Get informed when a big investor buys or sells
+ FollowMarket Cap$420.11M
Close$
$-9.51
155.2% downside
Current Fair Value
155.2% downsideOvervalued by 155.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $420.11 Million |
|---|---|
| Enterprise Value | $722.94 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.2 |
| Beta | 1.78 |
| Outstanding Shares | 25,925,600 |
Return
| Return on Equity | -6.60% |
|---|---|
| Return on Assets | -3.84% |
| Return on Invested Capital | -3.65% |
Valuation & Multiples
| P/E Ratio | -8.24 |
|---|---|
| PEG | 7.85 |
| Price to Sales | 0.59 |
| Price to Book Ratio | 0.58 |
| Enterprise Value to Revenue | 0.94 |
| Enterprise Value to EBIT | -15.91 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.62 |
| Debt to Equity | 0.57 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.03
Average shareholder expectationRevenue Estimate
$196.95 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$206.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 0.59% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.22%▼ 563.78% |
|---|---|
| Total Invested | $1.05M▼ 99.95% |
| Investors Holding | 9▼ 269.00% |
ESG Score
No data
About Neogenomics Inc.
1,600 employeesNeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...